10x Genomics, Inc. TXG Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s additional paid-in capital?
- 10x Genomics, Inc. (TXG) reported additional paid-in capital of $2.34B in Q1 2026.
- How has 10x Genomics, Inc.'s additional paid-in capital changed year-over-year?
- 10x Genomics, Inc.'s additional paid-in capital increased by 5.9% year-over-year, from $2.21B to $2.34B.
- What is the long-term trend for 10x Genomics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), 10x Genomics, Inc.'s additional paid-in capital has grown at a 8.4% compound annual growth rate (CAGR), from $1.54B to $2.31B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.